Drug adherence sits at the center of this dementia and brain health question.
Alzheimer’s drug adherence rates are significantly exceeding clinical expectations, particularly with lecanemab (Leqembi), which maintains a 78.4% continuation rate at 18 months and 67.3% at 24 months in long-term studies—substantially higher than the typical 60% adherence seen in other Alzheimer’s medications. Even more striking, 94% of patients who completed the initial 18-month trial period chose to continue treatment in extension studies, demonstrating robust patient acceptance despite the complexities of biweekly intravenous infusions and required MRI monitoring. This shift represents a meaningful change in how disease-modifying Alzheimer’s treatments perform in real-world settings, where patient persistence directly impacts cognitive outcomes and disease progression. This article examines why these newer anti-amyloid monoclonal antibodies are achieving better adherence than expected, explores the role of subcutaneous formulations in further improving treatment persistence, and discusses what these trends mean for patients and families facing early Alzheimer’s disease.
Table of Contents
- How Lecanemab Treatment Persistence Outpaces Other Alzheimer’s Medications
- IV Infusion Adherence: Overcoming Logistical Barriers to Disease-Modifying Treatment
- The Role of Subcutaneous Administration in Improving Adherence
- Comparing Treatment Options and Understanding the Durability Question
- Managing Adverse Events While Maintaining Treatment Persistence
- Real-World Evidence Beyond Clinical Trials
- The Future of Long-Acting and Patient-Centered Formulations in Alzheimer’s Treatment
- Conclusion
How Lecanemab Treatment Persistence Outpaces Other Alzheimer’s Medications
The contrast between lecanemab’s adherence rates and the broader landscape of Alzheimer’s medications is stark. Across all Alzheimer’s medications, weighted-average adherence sits at only 74.4%, with 70% of medication classes falling below 60% continuation rates. Lecanemab’s 78.4% rate at 18 months and 67.3% at 24 months significantly exceed these baselines, particularly when you consider that this drug requires a substantial commitment: biweekly intravenous infusions, amyloid PET scanning or biomarker confirmation before treatment, and ongoing MRI monitoring to assess for amyloid-related imaging abnormalities (ARIA). Traditional Alzheimer’s medications like donepezil, rivastigmine, and memantine are simple oral medications, yet they achieve lower persistence rates, suggesting that lecanemab’s higher adherence reflects something deeper than just convenience—likely the tangible cognitive benefits patients and caregivers observe.
The reasons for this superior persistence extend beyond the drug’s efficacy. Patients enrolled in studies and real-world cohorts show strong motivation to continue treatment after completing an initial 18-month period, with 94% electing to stay on therapy during long-term extensions. This choice is particularly meaningful because it occurs after patients have directly experienced both the benefits and side effects of treatment, suggesting that the cognitive stabilization or slowing of decline justifies the ongoing commitment. The structured nature of infusion-based therapy—regular clinical visits, contact with healthcare providers, and objective biomarker monitoring—may also reinforce adherence by keeping patients and caregivers engaged with the treatment plan in a way that daily oral medications sometimes don’t achieve.
IV Infusion Adherence: Overcoming Logistical Barriers to Disease-Modifying Treatment
Intravenous lecanemab administration represents a substantial logistical undertaking. Patients must arrange transportation to infusion centers, coordinate with caregivers for appointments, and manage potential adverse events that can occur during or after infusion. Systemic reactions occur in approximately 26% of IV recipients, including amyloid-related imaging abnormalities (ARIA), headaches, and infusion-related reactions, yet continuation rates remain high. This persistence despite real side effects underscores how meaningful the cognitive benefits must feel to families.
For many, maintaining daily function and slowing the progression toward more severe cognitive decline is worth the biweekly infusion commitment. However, adherence challenges are not uniform across all patient populations. Patients with limited mobility, those living in rural areas with restricted access to infusion centers, and individuals without reliable transportation face steeper barriers to maintaining their treatment schedule. Additionally, the requirement for amyloid biomarker confirmation and periodic MRI monitoring creates an initial assessment burden that screens out some patients before treatment ever begins. For those who do start, adverse events—particularly amyloid-related imaging abnormalities (ARIA) like microhemorrhages or microinfarcts on brain MRI—can complicate the decision to continue, though most patients do persist even after experiencing these complications if they remain asymptomatic.
The Role of Subcutaneous Administration in Improving Adherence
The FDA approval of subcutaneous lecanemab maintenance dosing in August 2025, followed by weekly subcutaneous dosing approval in January 2026, represents a significant shift in how this drug can be delivered. Subcutaneous administration eliminates the need for IV access, reduces time spent in infusion centers, and can be administered by trained nurses in various settings, including home-based administration in some cases. The safety profile of subcutaneous dosing is notably improved: systemic reactions occur in fewer than 1% of subcutaneous recipients compared to 26% with IV infusions, while only 11% experience mild-to-moderate local injection site reactions that do not interfere with continued treatment. This dramatic reduction in systemic adverse events removes a significant barrier to adherence.
Clinical and biomarker benefits are maintained when patients transition from 18 months of IV dosing to weekly subcutaneous maintenance, meaning the switch does not compromise efficacy. For patients who struggled with the IV infusion schedule or experienced bothersome systemic reactions, the ability to transition to weekly injections is likely to improve both adherence and quality of life. The weekly subcutaneous option is particularly valuable for patients who prefer less frequent dosing, though real-world data comparing adherence between biweekly IV and weekly subcutaneous formulations is still emerging. Early indicators suggest that reducing systemic adverse events will further improve treatment persistence, potentially pushing continuation rates even higher than the 67-78% range currently observed.
Comparing Treatment Options and Understanding the Durability Question
Patients and families often face a choice between starting lecanemab as early as possible—when cognitive reserve is highest—versus waiting for more long-term data or pursuing other approaches first. The emerging evidence on durability suggests that starting treatment earlier in disease progression and maintaining it long-term offers the best cognitive outcomes. Data showing 67-78% persistence rates over 24 months indicates that most patients who start treatment continue it, contrasting with older Alzheimer’s medications where most patients discontinue within a year. This persistence difference directly translates to cumulative drug exposure and greater opportunity for the anti-amyloid mechanism to slow cognitive decline.
The tradeoff for some families involves the commitment to ongoing monitoring and the real possibility of adverse events, particularly ARIA (amyloid-related imaging abnormalities), which appear on MRI in a subset of treated patients. Younger patients with greater life expectancy stand to benefit more from disease modification, making the long-term commitment more attractive. Conversely, patients in their 80s with significant comorbidities may prioritize quality-of-life measures like fewer medical appointments over modest cognitive slowing. The availability of subcutaneous dosing now provides a third option that previously didn’t exist, allowing clinicians to tailor delivery methods to individual preferences and circumstances.
Managing Adverse Events While Maintaining Treatment Persistence
Amyloid-related imaging abnormalities (ARIA) represent the most concerning adverse effect of lecanemab and other anti-amyloid monoclonal antibodies. ARIA can manifest as microhemorrhages (ARIA-H) visible on MRI or microinfarcts (ARIA-E), and occur in a significant percentage of treated patients, particularly those carrying the APOE4 genetic risk factor. However, most patients with asymptomatic ARIA remain on treatment, suggesting that the knowledge of potential microscopic brain changes—absent clinical symptoms—does not substantially reduce adherence. Symptomatic ARIA, characterized by cognitive fluctuations, headaches, or neurological changes, does prompt treatment discontinuation in some patients, though the frequency of truly symptomatic events is low.
Infusion-related reactions during IV administration can also affect adherence, though data suggests most patients successfully manage these events through premedication, slower infusion rates, or transitioning to subcutaneous dosing. The key predictor of sustained adherence appears to be whether patients experience benefit—stabilization of cognitive function or slower decline compared to expected progression—that they or their caregivers can recognize. When patients see or sense improvement or meaningful slowing of decline over months of treatment, adverse events that don’t cause symptoms become more tolerable. This is fundamentally different from traditional symptom-treating medications where patients expect to feel better almost immediately.
Real-World Evidence Beyond Clinical Trials
The high adherence rates reported in long-term extension studies reflect a controlled population of highly motivated patients who volunteered for research. Real-world data collected outside structured clinical trials provides a more pragmatic picture of how lecanemab persistence performs when offered to broader populations, including older adults, those with multimorbidity, and patients with less support.
Early real-world treatment persistence data from the United States, presented at major conferences, shows that patients continue lecanemab at rates nearly matching clinical trial cohorts, suggesting that the documented adherence advantage is not merely a research artifact. Reasons for persistence in real-world settings likely include direct communication with neurologists or memory care specialists about cognitive changes, family members who reinforce the importance of continued treatment, and the practical reality that missing a single dose feels more consequential when receiving biweekly infusions compared to simply not refilling a monthly prescription. Real-world cohorts also include patients who might not have enrolled in trials due to age, comorbidities, or other factors, yet still choose to continue treatment, expanding the applicability of these adherence findings beyond the narrow population typically studied in clinical trials.
The Future of Long-Acting and Patient-Centered Formulations in Alzheimer’s Treatment
The shift from biweekly IV dosing to weekly subcutaneous injection and the potential for future monthly or even longer-interval formulations reflects an evolving understanding of how disease-modifying treatments should be designed. Fewer injections, fewer clinic visits, and reduced adverse events collectively support higher adherence, and the pharmaceutical industry is responding. Other anti-amyloid monoclonal antibodies in late-stage development are exploring similar subcutaneous and extended-interval dosing strategies, signaling that the industry recognizes adherence-focused design as a competitive advantage.
Looking forward, the real opportunity lies in starting these treatments even earlier—in the preclinical or mild cognitive impairment stages of disease—when patients can benefit from years of disease slowing before dementia fully declares itself. The improved adherence rates and simplified formulations now available make this earlier-intervention model more feasible. As long-term safety and efficacy data accumulate beyond the current 24-month follow-up window, and as subcutaneous dosing becomes the standard, adherence rates may continue to improve, potentially reaching 80% or higher for some patient populations.
Conclusion
The exceptionally high adherence rates observed with lecanemab and other anti-amyloid monoclonal antibodies mark a turning point in Alzheimer’s disease treatment. With 67-78% of patients continuing IV treatment at 18-24 months, and 94% of initial responders choosing to continue in extension studies, these drugs demonstrate adherence profiles that substantially exceed the 60-74% baseline seen in other Alzheimer’s medications. The shift from intravenous to subcutaneous administration, with fewer systemic adverse events and simplified dosing schedules, promises to improve these rates further.
For patients and families facing early Alzheimer’s disease, these adherence trends carry practical implications: disease-modifying treatments with high persistence rates offer a realistic opportunity for meaningful cognitive benefit over years of treatment, not just months. Discussing lecanemab or similar anti-amyloid therapies with a neurologist should include candid conversations about the commitment required, the real possibility of adverse events like ARIA, and the realistic benefits based on current evidence. The fact that most patients who start treatment continue it—even knowing the side effects and monitoring demands—suggests that the cognitive stabilization or slower decline these drugs provide is tangible enough to justify the effort.
You Might Also Like
- Major Pharma Company’s Alzheimer’s Drug Candidate Fails Clinical Endpoint
- Regulatory Progress Tracked for Late-Stage Alzheimer’s Drug Candidates
- Philanthropic Grants Accelerate Alzheimer’s Drug Discovery
For more, see National Institute on Aging.
